speaker-icon

Latest Posts

Partex-EDCC-collaboration-illustration

3

Jun 24

Partex and Singapore’s Experimental Drug Development Centre collaborate to bring forward an innovative approach for early drug discovery and development

featured, Press release 2024
Frankfurt, Germany, 3rd June 2024, 9am CET Partex, a leading provider of AI-driven solutions in the pharmaceutical industry, is thrilled...
Read More
Partex-Lupin-press-release-illustration

23

Apr 24

Partex Partners with Lupin to Revolutionize Drug Discovery through AI-Driven Asset Search and Evaluation

featured, Press release 2024
Frankfurt, Germany, 23 April 2024 – Partex, a leading provider of AI-driven solutions in the pharmaceutical industry, is thrilled to...
Read More

Innoplexus wins Horizon Interactive Gold Award for Curia App

Read More
German VC firm invests in Data as a Service startup Innoplexus

German VC firm invests in Data as a Service startup Innoplexus

Innoplexus, a Germany- and India-based Data as a Service (DaaS) startup, has closed an undisclosed sum in pre-Series A funding from HCS, a Germany-based Venture VC firm.

With the capital, the startup plans to file more patent applications, further develop its trademark platform iPlexus, and invest in marketing.

Started in 2011, Innoplexus helps life sciences companies generate actionable insights across pre-clinical, clinical, regulatory and commercial stages of a drug. Its DaaS engine with real-time data and insights, along with an ecosystem of Continuous Analytics as a Service (CAaaS) applications, helps enterprises make better data-driven decisions.

Headquartered in Germany, with over 100 employees working from Pune, Innoplexus services large global pharma and life sciences companies. It helps companies move to continuous decision making by generating insights from structured and unstructured private and public data.

The company’s iPlexus platform helps life science firms to generate intelligence and insights across pre-clinical, clinical, regulatory and commercial stages of a drug across therapeutic areas and indications. It also helps researchers get quick, crisp and summarised snapshots of the current landscape in any given context through an intuitive semantic search, helping them make informed and data-backed decisions.

Dr. Gunjan Bhardwaj, Co-founder and CEO of Innoplexus, said, “We envision to fundamentally transform the DaaS landscape for life sciences by leveraging machine learning and artificial intelligence to generate insights from the public as well as enterprise data.”

Gaurav Tripathi, Co-founder and India CEO, said, “We are working in cutting-edge technology areas of Information Retrieval, Network Analysis, Computer Vision and Ontologies and are one of the rare startups with a strong focus on creating proprietary Intellectual Property.”

Featured News

Strategic partnership announcement: Innoplexus holding company Partex NV is pleased to announce a one-of-its-kind collaboration with Anavex Life science corp. for Artificial Intelligence (AI) enabled drug development and healthcare sales marketing anavex_partex_partnership_Innoplexus
on June 27, 2023

Strategic partnership announcement: Innoplexus holding company Partex NV is pleased

Exciting News! Anavex Life Sciences and Partex NV Announce Strategic Partnership to Enhance Patient Experience. Anavex Life Sciences Corp. and Partex NV N.V. Group are pleased to announce…

Read More